AHMED ABOUESH: Open Payments
NPI 1487661120 · CHICO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$963 in 43 payments from 15 companies in 2025. Trend: 2023 $956 · 2024 $753 · 2025 $963
Food & beverage: $963
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 6 | $141 |
| Teva Pharmaceuticals USA, Inc. | 7 | $139 |
| Neurocrine BioSciences, Inc. | 4 | $113 |
| ABBVIE INC. | 4 | $94 |
| Axsome Therapeutics, Inc. | 4 | $91 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $83 |
| Vanda Pharmaceuticals Inc. | 3 | $63 |
| E.R. Squibb & Sons, L.L.C. | 3 | $49 |
| Janssen Pharmaceuticals, Inc | 1 | $39 |
| Tris Pharma Inc | 2 | $34 |
Products named: INGREZZA, AUSTEDO XR, VRAYLAR, Auvelity, CAPLYTA, REXULTI, FANAPT, ABILIFY ASIMTUFII.
Industry payments across CA — which companies pay providers there.
